# A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

> **NCT04239833** · PHASE3 · UNKNOWN · sponsor: **Nanjing Sanhome Pharmaceutical, Co., Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** SH-1028 tablets
- **DRUG:** Placebo SH-1028 tablets
- **DRUG:** Gefitinib
- **DRUG:** Placebo Gefitinib

## Key facts

- **NCT ID:** NCT04239833
- **Lead sponsor:** Nanjing Sanhome Pharmaceutical, Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-31
- **Primary completion:** 2022-01-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04239833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04239833, "A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04239833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*